BioLife Solutions Q4 preliminary revenue $22.7M, +31% YoY; cell processing beats FY guidance

BIOLIFE SOLUTIONS INC

2024-FY EPS reported -$0.44 revenue$82,254,000

Q4 2024 continuing ops revenue $22.7M (+31% YoY); cell processing $20.3M (+37% YoY, +7% sequentially).
FY2024 continuing ops revenue $82.3M (+8% YoY); cell processing $73.5M exceeded raised guidance of $72-73M.
Evo and Thaw platform revenue fell 14% YoY to $8.7M for FY2024; Q4 down 8%.
Company completed divestitures of freezer and biostorage businesses, sharpening focus on CGT market.
CEO cites momentum, fortified balance sheet; full 2024 results and 2025 outlook due in February earnings call.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.